Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

achieved normalization of UFC after six months without dose up-titration relative to randomized dose(1). UFC is typically used to diagnose and monitor Cushing's disease. In this test, urine is collected over 24 hours to assess average cortisol secretion(2). The primary endpoint was met for the higher dose tested (900ug sc twice daily)(1). Secondary endpoints included safety, time to response, response duration and changes from baseline in clinical signs, symptoms, tumor volume and health-related quality of life(10).

After six months, the primary efficacy responder rate was 26.3% (95% confidence interval [CI], 16.6 to 35.9) and 14.6% (95% CI, 7.0 to 22.3), respectively, for the 900ug and 600ug groups. Based on pre-specified criteria (lower bound of 95% CI >15%), the 900ug group met the primary endpoint and the 600ug group did not meet the primary endpoint. After 12 months, the proportion of responders regardless of dose up-titration was 13.4% and 25.0%, respectively, for the 600ug and 900ug groups. The median reduction in UFC after six months was 47.9% for both groups. The median reduction in UFC after 12 months was 67.6% (600ug) and 62.4% (900ug). Patients who showed little to no improvement in UFC levels (<50% reduction from baseline) by month two were unlikely to show improvement by month six or 12. The most frequently reported adverse events suspected by the investigators to be related to the study drug were diarrhea (58%), nausea (46.9%), hyperglycemia (38.9%), cholelithiasis (29.6%), abdominal pain (20.4%), diabetes mellitus (17.9%), fatigue (11.7%) and increased glycosylated hemoglobin (10.5%), with most events being Grade 1-2. Overall, the tolerability profile of SOM230 is similar to other somatostatin analogs with the exception of the greater degree of hyperglycemia, which appears manageable with early detection and appropriate intervention following established treatment guidelines. As may be expected with a treatment that lowers co
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)...  Mylan Inc. (NASDAQ: MYL ) today announced ... Abbott (NYSE: ABT ) whereby ... markets specialty and branded generics business ("the Assets") in an ... receive 105 million shares of the combined company worth approximately ... Friday, July 11, 2014, representing an approximately 21% ownership stake. ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "Global Hypodermic Needles Market 2014-2018" report to ... A hypodermic needle is a hollow needle ... the body or or to extract fluids from it. ... liquids or to inject substances that cannot be ingested. ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... International Myeloma Workshop held in,Kos, Greece ... with bortezomib, dexamethasone and lenalidomide plus,dexamethasone, ... as a single agent in patients ... 29, 2007 /PRNewswire-FirstCall/ -- Keryx,Biopharmaceuticals, Inc. ...
... 2007--A cervical cancer vaccine has shown 90%,efficacy for prevention ... papillomavirus (HPV) types targeted by,the vaccine, conclude authors of ... of The Lancet., HPV types 16 and 18 account ... there are up to 15,oncogenic HPV types which can ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7Vaccine Can Prevent Cervical Cancer and Precancerous Lesions 2
(Date:7/14/2014)... Seattle, Wa (PRWEB) July 14, 2014 According ... Vkool.com, this is a helpful guide that features a series ... Vkool exposes in its review that this book can help ... common causes of high blood pressure, and effective methods to ... as they are reviewed now by Vkool, was penned by ...
(Date:7/14/2014)... Vaginal Mesh lawsuit claims continue ... pelvic mesh manufacturers in the U.S. District Court, Southern ... The federal complaints are pending against pelvic mesh manufacturers ... Systems (MDL No. 2325), and C.R. Bard, Inc., (MDL ... Vaginal Mesh lawsuit claims pending, according to statistics from ...
(Date:7/14/2014)... 14, 2014 TherapySites, ... mental health professionals, announced today its affiliation with ... Carolina (LPCANC). This new relationship allows TherapySites ... to LPCANC members, adding exclusive benefits and promotional ... have been dedicated to providing online marketing solutions ...
(Date:7/14/2014)... Townsend Security, a leading authority ... IBM i (AS/400, iSeries) Two Factor Authentication Partner ... threats evolve and make passwords ineffective for system ... their applications and implement two factor authentication (2FA). ... for ISVs on the IBM i platform to ...
(Date:7/13/2014)... N.J. – Authors Leonard I. Linkow and Sheldon ... implants in their book Renaissance of the ... techniques in the world of dentistry and reviews conventional and ... of their natural teeth. , Dr. Gustav Dahl of ... It was a mesh frame fabricated from stainless steel ...
Breaking Medicine News(10 mins):Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5Health News:TherapySites Partners With the Licensed Professional Counselors Association of North Carolina to Make Online Marketing Available to All Therapists 2Health News:IBM i ISVs Can Now Easily Integrate Mobile-Based Two Factor Authentication to Increase Security of Solutions 2Health News:IBM i ISVs Can Now Easily Integrate Mobile-Based Two Factor Authentication to Increase Security of Solutions 3Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 3Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 4
... may be more prone to an alcohol-induced headache after ... Jefferson Headache Center. The research will be presented at ... Neuroscience, in Chicago. Until now, studying the mechanism ... not been possible in an animal model, according to ...
... Macrophages, the scavenger cells of the body,s immune ... University School of Medicine researchers have identified one pathway ... causes a lupuslike autoimmune disease. The findings could ... of lupus in humans and potential drug treatments for ...
... e cigarettes sales have generally been tobacco smoking individuals ... online sales associate for E-Cigarettes National, reports an influx ... loved ones that smoke. "Some of these callers are ... starter kit for their spouses or partners that have ...
... is important to many who undergo weight-reduction surgery, study finds ... obese -- a step above overweight -- by the age ... polycystic ovarian syndrome than others, new research suggests. , ... than women who become obese when they,re older, according to ...
... cookie diets recently featured in the media have been criticized ... Smart for Life Cookie Diet should not be grouped in ... that are all-natural, 60% organic, and filled with nutrients and ... that has become much more than a simple cookie diet ...
... open enrollment season, and millions of employees are focusing ... a serious health issue strikes, it isn,t enough to ... on making sure you,re prepared to weather the storm ... this report from Guardian at: http://inr.mediaseed.tv/oneClip_C/?feed=BJ5vKAI3hMPsemBun4FIM6cBCcDeE0bZ ...
Cached Medicine News:Health News:Migraine sufferers more prone to hangover headache 2Health News:Stanford study identifies cellular mechanism that causes lupuslike symptoms in mice 2Health News:Stanford study identifies cellular mechanism that causes lupuslike symptoms in mice 3Health News:Online Sales of E Cigarettes Expected to Rise Over the Holidays 2Health News:Obesity May Affect Fertility in Young Women 2Health News:Smart for Life(TM) Cookie Diet Provides Nutrients 2Health News:Smart for Life(TM) Cookie Diet Provides Nutrients 3
OKN drum...
Accurately tests for Nystagmus when rotated at 8-10 rpm. Drums are 10" high by 8" diameter. Light weight drum of professional quality with ball bearings for effortless spin mechanism. For use 24 to 3...
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile...
The rectangular large-field lens of the 2631 are ideal for reading and writing....
Medicine Products: